Bruce Block
Donor Support Critical to Cancer Translational Research Unit
Philanthropy helps take treatment from the lab to the bedside
“The new Cancer Translational Research Unit is an important step toward providing the best patient care possible,” said Bruce Block, attorney and shareholder of Reinhart Boerner Van Deuren s.c. “It’s not easy to find a funding source within conventional channels, so this is where philanthropy can really lead the charge and help an important initiative move forward.”
Block is chair of a steering committee formed by the Froedtert Hospital Foundation board of directors with the goal of raising $5.6 million to support the creation and operation of the TRU. Other members of the steering committee include: Norman Barrientos, Andrew Haag, David Marcus, Jeffrey Metz, Marcy Neuburg, MD, Kip Ritchie, John Rosenberg, Michael Schroeder and Tom Smallwood.
“Froedtert & The Medical College make up a very strong research and teaching medical center, so it’s a pleasure to get involved,” Block said. “It’s a high quality organization and always striving for continued national excellence.”
uture cancer cures come from clinical research such as studies conducted every day at Froedtert & The Medical College of Wisconsin. As the robust clinical research at our academic medical center brings us closer to curing cancer, donor generosity helps bring important clinical trials to our community. The latest donor-supported advancement in cancer research is the effort to create a Cancer Translational Research Unit (TRU) that will offer early phase clinical trials at the Clinical Cancer Center (see page 7).
22
froedtert.com/cancer
Clinical Cancer Center
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24